會員登入
註冊
![[Digital Week]Enabling Industrialization of Human induced Pluripotent Stem Cells-Based Therapies](/upload/activity/activity_20210331024202_0.jpg)
[Digital Week]Enabling Industrialization of Human induced Pluripotent Stem Cells-Based Therapies
Register today to attend the BPI/ Cell & Gene Therapy Asia Digital Week, our free-to-attend webinar series delivering science, technologies and partners to improve timelines, drive down cosys and accelerate your biologics, stem cells, CAR-T and gene therapies to market.
- 日 期：2021-04-07
- 地 點：Digital Webinar
- 主辦單位：Informa Connect Life Sciences
- 活動網址
活動介紹
BioProcess International Asia：Cell & Gene therapy manufacturing & commercialization
April 5-8, 2021
Asia's Leading Bioprocessing Event For Learning How To Drive Down Costs, Improve Timelines,
And Navigate The Regulatory Landscape For Your Biologics And Novel Modalities
☑ Editors' choice｜DAY 3 – April 7, 2021 09:30 JST (Taiwan Time-08:30，Free event)
| Topic | Enabling Industrialization of Human induced Pluripotent Stem Cells-Based Therapies |
| Speaker | INBAR FRIEDRICH BEN-NUN / Sr. Manager, Cell and Gene Therapy R&D at Lonza |
| Content | The session key learning points include identifying the main manufacturing challenges for generation, expansion, and directed differentiation of human iPSC based cell therapies, the development of a cGMP compliant iPSC manufacturing process that supports efficient and unbiased directed differentiation into all three main germ layers, establishing an end-to-end platform allowing large scale expansion of high quality human iPSCs to support the required cell demand for various clinical indications, and addressing the key quality characteristics of human iPSCs with evaluation of the long-term cellular and genomic stability of Lonza GMP compliant iPSC lines. The session will highlight how Lonza can help the path towards commercialization of iPSC-based therapies. |
活動議程
DAY 1 – April 5, 2021
08:00 JST
Generation of Improved Host Cell Lines for Biomanufacturing using Vector & Cell Line Engineering Technologies
08:30 JST
Strategies in Expression of the SAFA Platform Based Fusion Proteins
09:00 JST
Apollo™X: Leveraging next generation technologies to achieve stable clonal cell lines expressing high product titers and intensified gene to GMP timelines
09:30 JST
DAY 2 – April 6, 2021
08:00 JST
High-throughput Robotics and State-of-the-Art Technologies to Enable Fast FIH with Engineered IgG Molecules
08:30 JST
Maximizing Virus Filtration Process Performance for High Protein Concentrations Using Planova™ BioEX
09:00 JST
MaruXTM: demonstrating continuous biomanufacturing at 500 L scale operations
09:30 JST
Novel Purification Technologies and Approaches to Maximize Speed, Efficiency and Process Optimization
10:00 JST
Ready for Biopharma 4.0? Accelerating your Process Development with Biopharma Lifecycle Management
10:30 JST
DAY 3 – April 7, 2021
08:00 JST
Allogeneic Cell Therapy Scaleup in a Stirred Tank Reactor
08:30 JST
COVID-19 Risk Mitigation Strategies for Cell and Gene Therapy Products
09:00 JST
Enabling Industrialization of Human induced Pluripotent Stem Cells-Based Therapies
09:30 JST
The Role of Virus Filtration in Achieving Pathogen Safety of Cell and gene Therapy Products
10:00 JST
Scalable Manufacturing of MSCs and iPSCs in Vertical-Wheel Bioreactors for Allogeneic Cell Therapies
10:30 JST
DAY 4 – April 8, 2021
08:00 JST
Generation of High Quality iPS Cells Using the SeV Vector System
08:30 JST
The Development of a Manufacturing Process for Multiple AAV Gene Therapy Vectors
09:00 JST
Scale Up and Risk Mitigation of Therapeutic Viral Vectors for Gene Therapy
09:30 JST
